ANI Pharmaceuticals, Inc. (ANIP)
USD 72.95
(3.2%)
USD 72.95
(3.2%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 18.77 Million USD | 139.21% |
| 2022 | -47.89 Million USD | -12.42% |
| 2021 | -42.6 Million USD | -88.94% |
| 2020 | -22.54 Million USD | -470.0% |
| 2019 | 6.09 Million USD | -60.67% |
| 2018 | 15.49 Million USD | 1539.96% |
| 2017 | -1.07 Million USD | -127.35% |
| 2016 | 3.93 Million USD | -74.41% |
| 2015 | 15.37 Million USD | -46.52% |
| 2014 | 28.74 Million USD | 9450.5% |
| 2013 | 301 Thousand USD | 101.09% |
| 2012 | -27.71 Million USD | 46.29% |
| 2011 | -51.6 Million USD | -11.72% |
| 2010 | -46.19 Million USD | 2.8% |
| 2009 | -47.52 Million USD | -172.75% |
| 2008 | -17.42 Million USD | -129.75% |
| 2007 | -7.58 Million USD | -371.72% |
| 2006 | 2.79 Million USD | 128.92% |
| 2005 | -9.65 Million USD | 19.68% |
| 2004 | -12.01 Million USD | -101.64% |
| 2003 | -5.95 Million USD | -56.39% |
| 2002 | -3.81 Million USD | -45.93% |
| 2001 | -2.61 Million USD | 24.03% |
| 2000 | -3.43 Million USD | -144.42% |
| 1999 | -1.4 Million USD | 47.12% |
| 1998 | -2.65 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 18.2 Million USD | 1476.36% |
| 2024 Q2 | -2.28 Million USD | -112.56% |
| 2023 FY | 18.77 Million USD | 139.21% |
| 2023 Q1 | 1.43 Million USD | 133.91% |
| 2023 Q2 | 6.24 Million USD | 333.98% |
| 2023 Q3 | 9.94 Million USD | 59.17% |
| 2023 Q4 | 1.15 Million USD | -88.38% |
| 2022 Q4 | -4.24 Million USD | 50.66% |
| 2022 FY | -47.89 Million USD | -12.42% |
| 2022 Q3 | -8.6 Million USD | 42.37% |
| 2022 Q1 | -20.13 Million USD | 16.6% |
| 2022 Q2 | -14.92 Million USD | 25.87% |
| 2021 Q1 | 81 Thousand USD | 102.23% |
| 2021 Q2 | -14.1 Million USD | -17514.81% |
| 2021 FY | -42.6 Million USD | -88.94% |
| 2021 Q3 | -4.44 Million USD | 68.47% |
| 2021 Q4 | -24.13 Million USD | -442.75% |
| 2020 Q2 | -12.33 Million USD | -75.95% |
| 2020 Q1 | -7.01 Million USD | -45.01% |
| 2020 Q3 | 422 Thousand USD | 103.42% |
| 2020 FY | -22.54 Million USD | -470.0% |
| 2020 Q4 | -3.63 Million USD | -961.37% |
| 2019 FY | 6.09 Million USD | -60.67% |
| 2019 Q4 | -4.83 Million USD | -226.17% |
| 2019 Q2 | 6.47 Million USD | 1372.27% |
| 2019 Q3 | 3.83 Million USD | -40.85% |
| 2019 Q1 | 440 Thousand USD | -91.82% |
| 2018 Q1 | 2.23 Million USD | 123.23% |
| 2018 Q3 | 4.98 Million USD | 81.38% |
| 2018 Q2 | 2.74 Million USD | 22.89% |
| 2018 FY | 15.49 Million USD | 1539.96% |
| 2018 Q4 | 5.37 Million USD | 7.84% |
| 2017 Q4 | -9.62 Million USD | -305.53% |
| 2017 FY | -1.07 Million USD | -127.35% |
| 2017 Q3 | 4.68 Million USD | 76.06% |
| 2017 Q2 | 2.66 Million USD | 133.22% |
| 2017 Q1 | 1.14 Million USD | 205.65% |
| 2016 Q2 | 1.11 Million USD | -16.58% |
| 2016 Q1 | 1.33 Million USD | -53.39% |
| 2016 FY | 3.93 Million USD | -74.41% |
| 2016 Q4 | -1.08 Million USD | -142.76% |
| 2016 Q3 | 2.52 Million USD | 126.14% |
| 2015 Q1 | 4.34 Million USD | -79.25% |
| 2015 Q2 | 3.54 Million USD | -18.38% |
| 2015 FY | 15.37 Million USD | -46.52% |
| 2015 Q3 | 4.52 Million USD | 27.69% |
| 2015 Q4 | 2.87 Million USD | -36.56% |
| 2014 Q3 | 6.66 Million USD | 381.89% |
| 2014 Q2 | -2.36 Million USD | -170.66% |
| 2014 Q4 | 20.94 Million USD | 214.41% |
| 2014 Q1 | 3.34 Million USD | -2.57% |
| 2014 FY | 28.74 Million USD | 9450.5% |
| 2013 Q1 | -2.29 Million USD | 42.55% |
| 2013 FY | 301 Thousand USD | 101.09% |
| 2013 Q4 | 3.43 Million USD | 192.84% |
| 2013 Q3 | 1.17 Million USD | 125.57% |
| 2013 Q2 | -4.58 Million USD | -100.09% |
| 2012 Q4 | -3.98 Million USD | 34.87% |
| 2012 Q2 | -7.34 Million USD | 28.45% |
| 2012 Q1 | -10.26 Million USD | -54.38% |
| 2012 FY | -27.71 Million USD | 46.29% |
| 2012 Q3 | -6.12 Million USD | 16.64% |
| 2011 Q3 | -12.73 Million USD | 14.97% |
| 2011 Q1 | -17.25 Million USD | -29.98% |
| 2011 FY | -51.6 Million USD | -11.72% |
| 2011 Q4 | -6.64 Million USD | 47.78% |
| 2011 Q2 | -14.97 Million USD | 13.19% |
| 2010 Q2 | -10.79 Million USD | -2.41% |
| 2010 FY | -46.19 Million USD | 2.8% |
| 2010 Q1 | -10.54 Million USD | 67.55% |
| 2010 Q4 | -13.27 Million USD | -14.51% |
| 2010 Q3 | -11.58 Million USD | -7.37% |
| 2009 Q1 | -4.05 Million USD | -247.58% |
| 2009 FY | -47.52 Million USD | -172.75% |
| 2009 Q3 | -6.37 Million USD | -37.87% |
| 2009 Q2 | -4.62 Million USD | -14.07% |
| 2009 Q4 | -32.48 Million USD | -409.94% |
| 2008 Q3 | -6.58 Million USD | -8.88% |
| 2008 Q2 | -6.04 Million USD | -66.77% |
| 2008 Q1 | -3.62 Million USD | -116.64% |
| 2008 FY | -17.42 Million USD | -129.75% |
| 2008 Q4 | -1.16 Million USD | 82.3% |
| 2007 Q2 | -2.4 Million USD | -32.1% |
| 2007 Q3 | -1.69 Million USD | 29.47% |
| 2007 Q1 | -1.81 Million USD | -120.21% |
| 2007 Q4 | -1.67 Million USD | 1.12% |
| 2007 FY | -7.58 Million USD | -371.72% |
| 2006 Q1 | -3.22 Million USD | -32.0% |
| 2006 FY | 2.79 Million USD | 128.92% |
| 2006 Q3 | -745.06 Thousand USD | 66.51% |
| 2006 Q4 | 8.98 Million USD | 1306.58% |
| 2006 Q2 | -2.22 Million USD | 31.09% |
| 2005 Q2 | -2.58 Million USD | 6.82% |
| 2005 Q4 | -2.44 Million USD | -31.97% |
| 2005 Q1 | -2.77 Million USD | 32.87% |
| 2005 Q3 | -1.85 Million USD | 28.21% |
| 2005 FY | -9.65 Million USD | 19.68% |
| 2004 Q2 | -2.57 Million USD | -5.27% |
| 2004 Q3 | -2.86 Million USD | -11.48% |
| 2004 Q4 | -4.12 Million USD | -43.82% |
| 2004 FY | -12.01 Million USD | -101.64% |
| 2004 Q1 | -2.44 Million USD | -47.33% |
| 2003 Q1 | -1.24 Million USD | -202.55% |
| 2003 FY | -5.95 Million USD | -56.39% |
| 2003 Q4 | -1.65 Million USD | -15.34% |
| 2003 Q3 | -1.43 Million USD | 10.96% |
| 2003 Q2 | -1.61 Million USD | -29.84% |
| 2002 FY | -3.81 Million USD | -45.93% |
| 2002 Q4 | -411.39 Thousand USD | 48.64% |
| 2002 Q3 | -801 Thousand USD | 46.43% |
| 2002 Q2 | -1.49 Million USD | -35.58% |
| 2002 Q1 | -1.1 Million USD | 21.87% |
| 2001 Q1 | -689.9 Thousand USD | 25.53% |
| 2001 Q4 | -1.41 Million USD | -504.31% |
| 2001 FY | -2.61 Million USD | 24.03% |
| 2001 Q3 | 349.16 Thousand USD | 140.65% |
| 2001 Q2 | -858.91 Thousand USD | -24.5% |
| 2000 Q4 | -926.46 Thousand USD | -49.25% |
| 2000 Q1 | -455.82 Thousand USD | 0.0% |
| 2000 FY | -3.43 Million USD | -144.42% |
| 2000 Q3 | -620.73 Thousand USD | 56.72% |
| 2000 Q2 | -1.43 Million USD | -214.64% |
| 1999 FY | -1.4 Million USD | 47.12% |
| 1999 Q2 | -279.38 Thousand USD | 0.0% |
| 1998 FY | -2.65 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Aquestive Therapeutics, Inc. | -7.87 Million USD | 338.615% |
| Collegium Pharmaceutical, Inc. | 48.15 Million USD | 61.003% |
| Cosmos Health Inc. | -18.54 Million USD | 201.275% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 193.627% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 108.975% |
| Cronos Group Inc. | -73.96 Million USD | 125.39% |
| Incannex Healthcare Limited | -18.45 Million USD | 201.734% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 144.501% |
| Lifecore Biomedical, Inc. | 12.01 Million USD | -56.322% |
| Regencell Bioscience Holdings Limited | -4.3 Million USD | 536.534% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 516.751% |
| Sunshine Biopharma, Inc. | -4.5 Million USD | 516.751% |
| SCYNEXIS, Inc. | 67.04 Million USD | 71.989% |
| Safety Shot Inc | -15.08 Million USD | 224.504% |
| Theratechnologies Inc. | -23.95 Million USD | 178.386% |
| Alpha Teknova, Inc. | -36.78 Million USD | 151.058% |
| Universe Pharmaceuticals INC | -6.16 Million USD | 404.702% |
| Pacira BioSciences, Inc. | 41.95 Million USD | 55.24% |
| Sonoma Pharmaceuticals, Inc. | -4.83 Million USD | 488.397% |
| Dynavax Technologies Corporation | -6.38 Million USD | 393.927% |
| Ironwood Pharmaceuticals, Inc. | -1 Billion USD | 101.874% |
| Radius Health, Inc. | -25.79 Million USD | 172.812% |
| China SXT Pharmaceuticals, Inc. | -3.09 Million USD | 706.061% |
| Alvotech | -551.73 Million USD | 103.404% |
| Intra-Cellular Therapies, Inc. | -139.67 Million USD | 113.445% |
| SIGA Technologies, Inc. | 68.06 Million USD | 72.412% |
| Shineco, Inc. | -22.44 Million USD | 183.652% |
| Silver Spike Investment Corp. | 7.34 Million USD | -155.841% |
| Journey Medical Corporation | -3.85 Million USD | 587.386% |
| Petros Pharmaceuticals, Inc. | -8.16 Million USD | 330.045% |
| Embecta Corp. | 70.4 Million USD | 73.325% |
| Harrow Health, Inc. | -24.41 Million USD | 176.928% |
| Procaps Group, S.A. | 42.54 Million USD | 55.856% |
| Biofrontera Inc. | -20.13 Million USD | 193.284% |
| DURECT Corporation | -27.62 Million USD | 167.981% |
| PainReform Ltd. | -9.34 Million USD | 300.974% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -1326.976% |
| OptiNose, Inc. | -35.48 Million USD | 152.924% |
| RedHill Biopharma Ltd. | 23.91 Million USD | 21.479% |
| Organogenesis Holdings Inc. | 4.94 Million USD | -279.757% |
| Cumberland Pharmaceuticals Inc. | -6.27 Million USD | 399.061% |
| ProPhase Labs, Inc. | -16.78 Million USD | 211.9% |
| Phibro Animal Health Corporation | 2.41 Million USD | -677.276% |
| Procaps Group S.A. | 42.54 Million USD | 55.856% |
| TherapeuticsMD, Inc. | -10.27 Million USD | 282.711% |
| Viatris Inc. | 54.7 Million USD | 65.669% |
| Rockwell Medical, Inc. | -8.43 Million USD | 322.526% |
| Aytu BioPharma, Inc. | -15.84 Million USD | 218.524% |
| Tilray Brands, Inc. | -244.98 Million USD | 107.665% |
| PetIQ, Inc. | 2.13 Million USD | -781.229% |
| Talphera, Inc. | -18.39 Million USD | 202.076% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 92.479% |
| Alimera Sciences, Inc. | -20.13 Million USD | 193.279% |
| Assertio Holdings, Inc. | -331.94 Million USD | 105.657% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6.59 Million USD | 384.844% |
| Avadel Pharmaceuticals plc | -160.27 Million USD | 111.717% |
| Hempacco Co., Inc. | -13.12 Million USD | 243.066% |
| Alvotech | -551.73 Million USD | 103.404% |
| Lantheus Holdings, Inc. | 326.66 Million USD | 94.251% |
| Kamada Ltd. | 8.28 Million USD | -126.69% |
| Currenc Group, Inc. | -15.3 Million USD | 222.686% |
| Indivior PLC | 2 Million USD | -838.95% |
| Evoke Pharma, Inc. | -7.79 Million USD | 340.994% |
| Flora Growth Corp. | -57.03 Million USD | 132.925% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 193.627% |
| Evolus, Inc. | -61.68 Million USD | 130.443% |
| HUTCHMED (China) Limited | 100.78 Million USD | 81.366% |
| Amphastar Pharmaceuticals, Inc. | 137.54 Million USD | 86.347% |
| Akanda Corp. | -32.27 Million USD | 158.184% |